In a recent video interview at the 24th Annual Fall Scientific Meeting of Sexual Medicine Society of North America, Dr. Mohit Khera provided valuable insights into the TRAVERSE trial (NCT03518034) and its findings on the safety of testosterone replacement therapy (TRT). Dr. Khera, a renowned professor of urology at Baylor College of Medicine, emphasized the significance of this trial as the largest randomized placebo-controlled study to date involving men receiving testosterone.
The TRAVERSE trial involved 5200 participants who were administered either testosterone gel or a placebo. One of the notable findings of this study was that there was no increased risk of cardiovascular events among men receiving testosterone therapy compared to those receiving the placebo. This groundbreaking result brings reassurance to individuals concerned about the potential cardiovascular risks associated with TRT.
Additionally, the study examined the impact of testosterone therapy on sexual function. While it did not significantly improve erectile function, it consistently enhanced libido in the participants for up to two years. These findings highlight the potential benefits of TRT in improving sexual desire and satisfaction.
Moving forward, the TRAVERSE trial holds promise for uncovering further outcomes related to anemia, bone mineral density, depression, diabetes, and more. Although only the cardiovascular and sexual function results have been published thus far, exciting results from the subsequent studies are eagerly anticipated.
The TRAVERSE trial sheds light on the safety and benefits of testosterone replacement therapy, dispelling concerns about cardiovascular risks. With ongoing research, we can expect a more comprehensive understanding of the potential advantages and effects of TRT in various aspects of men’s health and well-being.
Frequently Asked Questions (FAQ)
1. Is testosterone replacement therapy safe?
The TRAVERSE trial, the largest randomized placebo-controlled study on testosterone replacement therapy, found no increased risk of cardiovascular events among men receiving testosterone.
2. Does testosterone therapy improve sexual function?
While testosterone therapy did not significantly improve erectile function, it consistently enhanced libido in participants for up to two years, as observed in the TRAVERSE trial.
3. What other outcomes were assessed in the TRAVERSE trial?
In addition to cardiovascular and sexual function results, the TRAVERSE trial also examined outcomes related to anemia, bone mineral density, depression, diabetes, and more. Results from these studies are yet to be published.
4. Who conducted the TRAVERSE trial?
The TRAVERSE trial was conducted by Dr. Mohit Khera, a professor of urology at Baylor College of Medicine in Houston, Texas, and the outgoing president of the Sexual Medicine Society of North America (SMSNA).
Sources:
– [Sexual Medicine Society of North America](https://www.smsna.org/)